FDA approves Shire's extended-release ADHD drug

09/3/2009 | Reuters

The FDA approved Shire's Intuniv, an extended-release drug for attention-deficit/hyperactivity disorder in children ages 6 to 17. The British company said the drug, the first selective alpha-2A receptor agonist for ADHD, is expected to be available at U.S. pharmacies in November.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC